ScreenCancer scores exclusive deal for Quest's InSure FIT
This article was originally published in Clinica
Norwegian cancer screening services provider ScreenCancer is to be the exclusive European distributor of InSure FIT, a "take-at-home" colorectal cancer screening test developed by Quest Diagnostics' subsidiary Enterix. The two-year deal will see Sandnes-based ScreenCancer offer the test to its customers in 24 European countries, including France, Germany and the UK. The InSure FIT (faecal immunochemical test) will be added to the panel of cancer screening products offered by ScreenCancer to privately-insured patients. The InSure FIT is designed for easy sample collection, which, in turn, will help increase patient compliance and enable early intervention. Unlike other FITs or faecal occult blood tests which require patients collect solid stool samples, the InSure FIT features a long-handled brush which is used to brush the surface of the stool. Only two samples are required for the InSure FIT and patients do not have to change their diets or medications during sample collection.
You may also be interested in...
Minimally invasive glaucoma surgery specialist Glaukos saw its stock leap 40% in the wake of a worldwide recall by much bigger rival Alcon of its CyPass microstent.
Roland Diggelmann will end his decade-long career at Roche Diagnostics at the end of September. The business's head of EMEA Michael Heuer will take Diggelmann's place while the search is on for his replacement.
Philips has added a new pulse oximetry platform to its patient monitoring portfolio, with the acquisition of Xhale Assurance.